The pharmacological agent outperforms current drugs in most of cases, show multiple experiments
A new pharmacological agent demonstrates promising results for the prevention of a wide range of heart rhythm disorders, including both cardiac and brain injury-induced arrhythmias. Furthermore, the compound (SS-68) demonstrates significant activity in conditions of reduced blood flow to the heart caused by obstructed arteries.
Each year, more than 17 million people from around the globe (mostly Europe and the USA) die of cardiovascular diseases and related complications, according to the World Health Organization. In Russia, about 3 out of 1,000 people suffer from the most common and malignant heart rhythm disorder: atrial fibrillation (AF), where the count is expected to at least double in the next 30 years. While sometimes lacking symptoms, atrial fibrillation could generally be recognised by a racing, irregular heartbeat, dizziness, fatigue, shortness of breath and chest pain, thereby largely compromising the quality of one’s life. The disorder could also lead to various complications, including dementia, stroke and heart failure.
Currently, the drugs administered to AF patients have major deficiencies, including narrow therapeutic windows, which means that even minimal imprecision in the dosage could result in unacceptable toxicity. Hence, patients need to be closely monitored and have their doses adjusted on a regular basis.
In their study, the team turned to the aminoindole derivatives to look for an alternative compound. This chemical group has already shown a significant potential in terms of cardio-pharmacological activity.
Having tested the SS-68 compound on multiple occasions in different animals, the researchers report that it has a pronounced antiarrhythmic effect and is able to bring the electrical activity of the heart back to normal and, in most cases, outperforming the reference drugs used in clinical practice: amiodarone, lidocaine, aymaline, ethacizine, etmozine and quinidine anaprilin.
Further, in brain injury-induced arrhythmias, the compound was found to reduce the episodes of epilepsy. It was also observed to have a positive effect in clogged blood vessels where it is reported to have successfully increased the coronary blood flow. In addition, the compound managed to decrease the area of necrosis in the heart tissue caused by a heart attack.
“To date, there have been significant achievements of Russian and foreign pharmacologists, chemists and clinicians in creating and introducing into the practical medicine a number of antiarrhythmic drugs different by their chemical structure, nature, spectrum, activity and mechanism of action; nevertheless, one of the most important tasks of modern pharmacology is searching for and developing new highly active substances of the corresponding action,” explain the scientists.
“Special attention should be paid to an in-depth study of the molecular mechanisms of action of this compound,” they conclude.
A paper looking further into the molecular mechanisms of the antiarrhythmic action of SS-68 prepared by the same research team is currently in press with Research Results in Pharmacology.
The Latest on: Pharmacological agent
[google_news title=”” keyword=”pharmacological agent” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pharmacological agent
- Cell therapy process for heart regeneration may advance treatment of cardiovascular diseaseon November 21, 2022 at 1:53 pm
A researcher at the University of Houston College of Pharmacy is reporting an effective protocol for reprogramming human heart cells into specialized cells that conduct electricity throughout the ...
- Discovery May Advance Treatment of Cardiovascular Diseaseon November 21, 2022 at 8:25 am
Currently, there are no treatments for cardiac cell death, the underlying basis of cardiovascular disease (CVD), which remains the leading cause of death globally. By 2035, CVD prevalence is expected ...
- Stress Ulcer Prophylaxis in the Postoperative Periodon November 19, 2022 at 3:59 pm
In addition, the majority of recently published prospective studies and a meta-analysis have been unable to demonstrate a reduction in clinically important bleeding with pharmacologic agents.
- Further Evaluation of the Tyramine Test for Pheochromocytomaon November 16, 2022 at 4:01 pm
Our own intention, and the motivation in seeking a new pharmacologic agent for testing, was to avoid the nausea, vomiting, headache and potentially lethal hypertensive responses associated with ...
- Drug-Induced Urinary Incontinenceon November 16, 2022 at 4:01 pm
Each of the processes described previously can be manipulated by pharmacologic agents to cause one or more types of incontinence. If it is not possible to discontinue the antipsychotic ...
- Potential New Compounds Identified for Treatment of Depression and Anxiety Disorderson November 16, 2022 at 1:36 am
Researchers have identified new drugs that could potentially be used to treat neuropsychiatric disorders. These compounds displayed a reduced risk of adverse effects compared to other agents currently ...
- Researchers identify potential lead compounds for the treatment of neuropsychiatric disorderson November 15, 2022 at 7:33 pm
Currently, various classes of drugs are available for the treatment of mental illnesses - such as depression and anxiety disorders. However, although these drugs confer benefits, they are also ...
- Potential new lead compounds for the treatment of depression and anxiety disorderson November 15, 2022 at 12:28 pm
Currently, various classes of drugs are available for the treatment of mental illnesses -- such as depression and anxiety disorders. However, although these drugs confer benefits, they are also ...
- Updated CDC guidelines for prescribing opioidson November 9, 2022 at 3:58 pm
Opioids are common pharmacological agents that are used to manage pain; however, the long-term use of these agents increases the risk of overdose and misuse. Notably, both immediate- and ...
via Bing News